DigestRedComo funciona
Red
/
Empresas
OS
No verificado

OS Therapies, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

14 Comunicados de prensa

Ver todos los comunicados de prensa
13/03/2025
Eventos
Ferias y Congresos
Industria
Ciencia
Medicina - Varios
Biotecnología
Sanidad
Salud
Farmacéutica
Oncología
OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference
Fuente
OS Therapies, Inc.
Editor
Business Wire
1.00
0
11/03/2025
Eventos
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma
Fuente
OS Therapies, Inc.
Editor
Business Wire
1.00
0
24/02/2025
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms
Fuente
OS Therapies, Inc.
Editor
Business Wire
1.00
0
20/02/2025
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2
Fuente
OS Therapies, Inc.
Editor
Business Wire
1.00
0
14/02/2025
Oncología
Salud
Higiene alimentaria
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
Mercado laboral
Industria
OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing
Fuente
OS Therapies, Inc.
Editor
Business Wire
1.00
0
04/02/2025
Biotecnología
Higiene alimentaria
Salud
Sanidad
Farmacéutica
Oncología
Ciencia
Veterinaria
Medicina - Varios
Industria
OS Therapies Provides Corporate Update
Fuente
OS Therapies, Inc.
Editor
Business Wire
1.00
0
15/01/2025
Análisis de Mercados
Industria
Ciencia
Biotecnología
Farmacéutica
Oncología
Sanidad
Salud
Medicina - Varios
OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma
Fuente
OS Therapies, Inc.
Editor
Business Wire
1.00
0
15/01/2025
Análisis de Mercados
Industria
Ciencia
Biotecnología
Farmacéutica
Oncología
Sanidad
Salud
Medicina - Varios
OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma
Fuente
OS Therapies, Inc.
Editor
Business Wire
1.00
0
02/01/2025
Eventos
Ferias y Congresos
Oncología
Salud
Ciencia
Farmacéutica
Biotecnología
OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference
Fuente
OS Therapies, Inc.
Editor
Business Wire
1.00
0
31/12/2025
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
OS Therapies Announces Closing of $6 Million Private Placement
Fuente
OS Therapies, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0